Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index; 83 of the 118 sources its claims cite were checked for support.

Macrophage duality in liver diseases: heterogeneity, plasticity, and the quest for precision therapeutics

Open access

Abstract

Liver macrophages are master regulators of disease progression and resolution, whose functions transcend the simplistic M1/M2 dichotomy. This review synthesizes cutting-edge evidence to establish a dynamic, subset-centric paradigm for understanding macrophage plasticity. In acute liver injury, we delineate how temporally segregated subsets (e.g., early CCR2 + vs. late MerTK + macrophages) sequentially orchestrate damage and repair. In chronic settings—including HBV infection, MASLD/MASH, and fibrosis/cirrhosis—we reveal a complex coexistence of functionally opposed subsets that concurrently drive pathology (e.g., CD9 + TREM2 + macrophages) and promote resolution (e.g., CD300E + macrophages). This refined understanding underpins a critical appraisal of the evolving therapeutic landscape, which is pivoting from broad immunosuppression towards precision strategies. These include pharmacological targeting of specific recruitment or signaling pathways, adoptive transfer of reparative subsets, and innovative engineered cell therapies (e.g., signal-converting CAR-Ms). By framing macrophage functional duality within the “friend or foe” paradigm, this review provides a conceptual framework for developing subset-specific therapies that harness the beneficial while mitigating the harmful faces of hepatic macrophages. We highlight that the key translational challenge lies in mastering macrophage heterogeneity—requiring resolution of in vivo dynamics, cross-species discrepancies, and achievement of durable, context-specific modulation. The future of “macrophage medicine” hinges on integrating spatial multi-omics and advanced imaging to enable spatiotemporally precise interventions, ultimately leveraging the cell’s inherent plasticity for therapeutic gain.

Overview

CoChat Summary

TL;DR

This is a narrative review arguing that liver macrophages cannot be understood with a simple M1/M2 framework and instead should be viewed as dynamic, subset-specific actors that can either worsen or resolve liver disease. It also reviews a shift in therapy from broad immunosuppression to precision approaches such as subset-targeted drugs, adoptive transfer, and engineered macrophages.

Key findings

  • In acute liver injury, macrophage functions change over time: early CCR2+ monocyte-derived macrophages drive damage, while later reparative subsets such as MerTK+ macrophages, CXCR4+ macrophages, TREM2+ LAMs, and MARCO+ macrophages support resolution and repair.
  • In chronic liver disease, distinct subsets can simultaneously promote pathology and protection: examples include pro-inflammatory CD205+ macrophages in HBV, S100A4+ MoMFs and CD11chiMinclehi hLAMs in MASLD/MASH, and CD9+TREM2+ macrophages in fibrosis, alongside protective subsets such as OPN+ macrophages, CD209a-expressing macrophages, and CD300E+ MoMFs.
  • Therapeutic translation is mixed: Cenicriviroc failed in the AURORA phase III trial to significantly alleviate fibrosis in NASH, while combination approaches and cell-based strategies show stronger promise in preclinical work.
  • Clinical cell therapy evidence is early but encouraging: a phase I trial of autologous monocyte-derived macrophage reinfusion in cirrhosis was safe and was associated with improved MELD score and liver stiffness, but a later phase II randomized trial did not meet its primary endpoint at 90 days.

Methods

  • Narrative review/synthesis of published studies on liver macrophage biology and therapy across acute injury, HBV, MASLD/MASH, and fibrosis/cirrhosis.
  • Integrates evidence from experimental models, human patient studies, single-cell and single-nucleus RNA sequencing studies, and clinical trials.
  • Main analytic approach is conceptual and comparative: it organizes macrophage subsets by disease context, timing, function, and therapeutic implications rather than performing a new quantitative meta-analysis.

Limitations

  • The paper states that key translational challenges remain: unresolved in vivo subset dynamics, cross-species discrepancies, and difficulty achieving durable, context-specific modulation.
  • It also notes gaps in knowledge about spatiotemporal relationships, lineage relationships, and the master regulators of phenotypic switching.
  • Evident from the text: this is a review, so it does not present new primary data or a systematic quantitative synthesis of effect sizes.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fimmu.2026.1814879

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Macrophage duality and therapeutic strategies in liver diseases. (A, B) Schematic overview of functionally distinct macrophage subsets in acute and chronic liver disease. Pro-inflammatory/pathogenic subsets (Foes, left) and pro-resolving/reparative subsets (Friends, right) are shown with their phenotypic markers and key functions. Their temporal shift or coexistence dictates outcome. (C) Evolution of macrophage-targeted therapeutic strategies. From left to right: pharmacological inhibition (e.g., CCR2/5 antagonist); adoptive transfer of reparative subsets (e.g., AAMs); engineered cell therapies (e.g., CAR-Ms) and inducing macrophage death. MoMFs, monocyte-derived macrophages; DAMP, damage-associated molecular pattern; TREM2, triggering receptor expressed on myeloid cells 2; LAMs, lipid-associated macrophages; PDGF, platelet-derived growth factor; HSCs, hepatic stellate cells; IL, interleukin; TNF, tumor necrosis factor; GM-CSF, granulocyte-macrophage colony stimulating factor; TCR, T cell receptor; HBV, hepatitis B virus; OPN, osteopontin; Notch-RBPJ, Notch-Recombination signal binding protein for immunoglobulin kappa J; NLRP3, NOD-like receptor protein 3; ECM, extracellular matrix; NAMPT, nicotinamide phosphoribosyltransferase; CVC, cenicriviroc; MMP1, matrix metalloproteinase 1; CAR-Ms, chimeric antigen receptor macrophages; TgMIF, Toxoplasma gondii macrophage migration inhibitory factor; uPAR, urokinase plasminogen activator receptor; TNC, tenascin-C.
Figure 1 Macrophage duality and therapeutic strategies in liver diseases. (A, B) Schematic overview of functionally distinct macrophage subsets in acute and chronic liver disease. Pro-inflammatory/pathogenic subsets (Foes, left) and pro-resolving/reparative subsets (Friends, right) are shown with their phenotypic markers and key functions. Their temporal shift or coexistence dictates outcome. (C) Evolution of macrophage-targeted therapeutic strategies. From left to right: pharmacological inhibition (e.g., CCR2/5 antagonist); adoptive transfer of reparative subsets (e.g., AAMs); engineered cell therapies (e.g., CAR-Ms) and inducing macrophage death. MoMFs, monocyte-derived macrophages; DAMP, damage-associated molecular pattern; TREM2, triggering receptor expressed on myeloid cells 2; LAMs, lipid-associated macrophages; PDGF, platelet-derived growth factor; HSCs, hepatic stellate cells; IL, interleukin; TNF, tumor necrosis factor; GM-CSF, granulocyte-macrophage colony stimulating factor; TCR, T cell receptor; HBV, hepatitis B virus; OPN, osteopontin; Notch-RBPJ, Notch-Recombination signal binding protein for immunoglobulin kappa J; NLRP3, NOD-like receptor protein 3; ECM, extracellular matrix; NAMPT, nicotinamide phosphoribosyltransferase; CVC, cenicriviroc; MMP1, matrix metalloproteinase 1; CAR-Ms, chimeric antigen receptor macrophages; TgMIF, Toxoplasma gondii macrophage migration inhibitory factor; uPAR, urokinase plasminogen activator receptor; TNC, tenascin-C.CC BY · PubMed Central

Verification

Claims the paper makes

69 Valid · 1 Not valid · 27 Not checked · 29 Own results and interpretations

57 more claims · 31 with their cited sources checked

Create a free account to see all 126 claims and to verify the 14 references still open.

See all claims — free account
  • It may state two separate claims as one. 58
  • Probably not a substantial claim. 8
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 81 references

Cited by

See all 1

Metadata

Authors
Chen, L., Chen, Y., Zhao, M., Yang, X., Sutte, K., Lu, M., Chen, J., Zheng, X., Yang, D., & Liu, J.
Affiliations
  • Wuhan Union Hospital (CN)
  • Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  • Essen University Hospital (DE)
  • Shanghai Medical College of Fudan University (CN)
Corresponding author
Liu, Jia
Venue
Frontiers in Immunology
Published
2026-04-14
Volume
17
Pages
1814879-1814879
ISSN
1664-3224 (ISSN-L)
OpenAlex
W7154260907
Cited by
1
References
81
Citations by year
2026: 1
FWCI
1.23
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Key Research and Development Program of China (2023YFC2308502)
  • National Natural Science Foundation of China (82172256, 92169105, M-0060, 82202037)
  • Natural Science Foundation of Hubei Province (2025AFD795)
  • National Mega Project on Major Infectious Disease Prevention (2026ZD01912302)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
Keywords
hepatic macrophages, macrophage plasticity, CCR2+ macrophages, acute liver injury, chronic liver disease, hepatitis B virus, liver fibrosis, liver cirrhosis, adoptive macrophage transfer, macrophage recruitment, spatial multi-omics, liver regeneration
MeSH terms
Cell Plasticity, Animals, Humans, Liver Diseases, Macrophages, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Macrophage duality in liver diseases: heterogeneity, plasticity, and the quest for precision therapeutics. https://app.cochat.ai/papers/10.3389/fimmu.2026.1814879
The paper
Chen, L., Chen, Y., Zhao, M., Yang, X., Sutte, K., Lu, M., Chen, J., Zheng, X., Yang, D., & Liu, J. (2026). Macrophage duality in liver diseases: heterogeneity, plasticity, and the quest for precision therapeutics. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1814879

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.